

# VU Research Portal

## Tumor cell resistance to antiangiogenic receptor tyrosine kinase inhibitors

Gotink, K.J.

2016

### **document version**

Publisher's PDF, also known as Version of record

[Link to publication in VU Research Portal](#)

### **citation for published version (APA)**

Gotink, K. J. (2016). *Tumor cell resistance to antiangiogenic receptor tyrosine kinase inhibitors*. [PhD-Thesis - Research and graduation internal, Vrije Universiteit Amsterdam].

### **General rights**

Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the public portal ?

### **Take down policy**

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

### **E-mail address:**

[vuresearchportal.ub@vu.nl](mailto:vuresearchportal.ub@vu.nl)

## Contents

<b>Chapter 1</b>	General introduction and outline of the thesis	7
<b>Chapter 2</b>	Anti-angiogenic tyrosine kinase inhibitors: what is their mechanism of action? <i>Angiogenesis. 2010;13:1-14</i>	15
<b>Chapter 3</b>	Lysosomal sequestration of sunitinib: a novel mechanism of drug resistance <i>Clin Cancer Res. 2011;17:7337-46</i>	43
<b>Chapter 4</b>	Acquired tumor cell resistance to sunitinib causes resistance in a HT-29 human colon cancer xenograft mouse model without affecting sunitinib biodistribution or the tumor microvasculature <i>Oncoscience. 2014;1:844-53</i>	63
<b>Chapter 5</b>	Cross-resistance to clinically used tyrosine kinase inhibitors sunitinib, sorafenib and pazopanib <i>Cell Oncol. 2015;38:119-29</i>	83
<b>Chapter 6</b>	Evaluation of a tyrosine kinase peptide microarray for TKI therapy selection in cancer <i>Submitted</i>	103
<b>Chapter 7</b>	Summarizing discussion and future perspectives	129
	Summary	140
	Nederlandse samenvatting	144
	Dankwoord	148
	Curriculum Vitae	152
	List of publications	153